SEHK:2269Life Sciences
Assessing WuXi Biologics (SEHK:2269) Valuation After PatroLab Launch And New UK MHRA GMP Certifications
WuXi Biologics (Cayman) (SEHK:2269) is in focus after receiving UK MHRA GMP certifications for two Wuxi facilities and unveiling its PatroLabTM digital twin platform, developments that may reshape how investors view its outsourcing capabilities.
See our latest analysis for WuXi Biologics (Cayman).
The recent UK MHRA GMP certifications and the launch of PatroLabTM arrive while WuXi Biologics’ share price has climbed to HK$39.78, with a 1-year total shareholder return of 126.02% but negative...